Report of Foreign Issuer (6-k)
16 August 2019 - 11:08PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
August 16, 2019
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
|
Form 20-F [X]
|
Form 40-F [ ]
|
Indicate by check mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g-32(b):82-________
Securities lawsuit filed in
Denmark against Novo Nordisk
Bagsværd, Denmark, 16 August 2019
-
Novo Nordisk A/S has today been informed that a securities lawsuit has been filed against the company in Denmark.
The lawsuit is filed by a number of shareholders.
The claim is for a total amount of DKK 11,785,192,218 based on their trading and holding of shares in Novo Nordisk A/S during the
period 3 February 2015 to 2 February 2017.
The lawsuit alleges that Novo Nordisk made
misleading statements and did not make appropriate disclosures regarding its sales of insulin products in the USA. The lawsuit
appears to contain broadly similar allegations to those of the previously announced securities class-action lawsuit filed in the
USA in 2017 on behalf of all purchasers of Novo Nordisk American Depository Receipts (ADRs).
Novo Nordisk disagrees with the allegations
and is prepared to defend the company in this matter.
Novo Nordisk is a global healthcare
company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities
that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered
in Denmark, Novo Nordisk employs approximately 41,600 people in 80 countries and markets its products in more than 170 countries.
Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For
more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
Page 2 of 2
Further information
|
Media:
|
|
|
|
Katrine Sperling
|
+45 3079 6718
|
krsp@novonordisk.com
|
|
Ken Inchausti (US)
|
+1 609 240 9429
|
kiau@novonordisk.com
|
|
|
|
|
|
Investors
:
|
|
|
|
Peter Hugreffe Ankersen
|
+45 3075 9085
|
phak@novonordisk.com
|
|
Valdemar Borum Svarrer
|
+45 3079 0301
|
jvls@novonordisk.com
|
|
Ann Søndermølle Rendbæk
|
+45 3075 2253
|
arnd@novonordisk.com
|
|
Kristoffer Due Berg US)
|
+1 609 235 2989
|
krdb@novonordisk.com
|
|
Novo Nordisk A/S
Investor Relations
|
Novo Allé
2880 Bagsværd
Denmark
|
Telephone:
+45 4444 8888
|
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
|
|
|
|
Company announcement No 48 / 2019
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
|
Date: August 16, 2019
|
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer
|
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Apr 2023 to Apr 2024
